ACS Medicinal Chemistry Letters
Letter
(15) Barlaam, B.; Acton, D. G.; Ballard, P.; Bradbury, R. H.; Cross,
D.; Ducray, R.; Germain, H.; Hudson, K.; Klinowska, T.; Magnien, F.;
Ogilvie, D. J.; Olivier, A.; Ross, H. S.; Smith, R.; Trigwell, C. B.;
Vautier, M.; Wright, L. Neutral 5-substituted 4-indazolylaminoquina-
zolines as potent, orally active inhibitors of erbB2 receptor tyrosine
kinase. Bioorg. Med. Chem. Lett. 2008, 18, 1799−1803.
́
the compounds: Annie Olivier, Herve Germain, Christian
Delvare, Delphine Dorison-Duval, Jennifer Vincent, Rowena
Callis, Sara Davenport, Helen Ross, Robin Smith, and Frederic
Ducrozet. We warmly thank Dr. Ann Ertan (AstraZeneca
Sodertalje) for determining the X-ray crystal structure of 2.
̈
(16) Hickinson, D. M.; Klinowska, T.; Speake, G.; Vincent, J.;
Trigwell, C.; Anderton, J.; Beck, S.; Marshall, G.; Davenport, S.; Callis,
R.; Mills, E.; Grosios, K.; Smith, P.; Barlaam, B.; Wilkinson, R. W.;
Ogilvie, D. AZD8931, an Equipotent, Reversible Inhibitor of Signaling
by Epidermal Growth Factor Receptor, ERBB2 (HER2), and ERBB3:
A Unique Agent for Simultaneous ERBB Receptor Blockade in
Cancer. Clin. Cancer Res. 2010, 16, 1159−1169.
REFERENCES
■
(1) Olayioye, M. A.; Neve, R. M.; Lane, H. A.; Hynes, N. E. The
ErbB signaling network: receptor heterodimerization in development
and cancer. EMBO J. 2000, 19, 3159−67.
(2) Jorissen, R. N.; Walker, F.; Pouliot, N.; Garrett, T. P.; Ward, C.
W.; Burgess, A. W. Epidermal growth factor receptor: mechanisms of
activation and signalling. Exp. Cell. Res. 2003, 284, 31−53.
(3) Citri, A.; Skaria, K. B.; Yarden, Y. The deaf and the dumb: the
biology of ErbB-2 and ErbB-3. Exp. Cell. Res. 2003, 284, 54−65.
(4) Salomon, D.; Gullick, W. The erbB family of receptors and their
ligands: multiple targets for therapy. Signal 2001, 2, 4−11.
(5) Ciardiello, F.; Tortora, G. EGFR antagonists in cancer treatment.
N. Engl. J. Med. 2008, 358, 1160−74.
(17) Previously described in Himmelsbach, F.; Jung, B.; Solca, F. Int.
Pat. Appl. WO 2003082290.
(18) Carter, C. A.; Kelly, R. J.; Giaccone, G. Small-molecule
inhibitors of the human epidermal receptor family. Expert Opin. Invest.
Drugs 2009, 18, 1829−1842.
(19) Stamos, J.; Sliwkowski, M. X.; Eigenbrot, C. Structure of the
epidermal growth factor receptor kinase domain alone and in complex
with a 4-anilinoquinazoline inhibitor. J. Biol. Chem. 2002, 277, 46265−
272.
(20) Homology model was built using the PRIME homology
modeling program. Prime, 1.0 ed.; Schrodinger, Inc. Compound 2 has
been docked manually by analogy to the docking mode of Erlotinib
inhibitor in the reference structure 1M17. Images in Figure 2 have
been created in VIDA v4 from OpenEye Scientific Software, 3600
Cerrillos Rd., Suite 1107, Santa Fe, NM 87507.
(21) Allen, F. H. The Cambridge Structural Database: a quarter of a
million crystal structures and rising. Acta Crystallogr. 2002, B58, 380−
388.
(22) Berman, H. M.; Westbrook, J.; Feng, Z.; Gilliland, G.; Bhat, T.
N.; Weissig, H.; Shindyalov, I. N.; Bourne, P. E. The Protein Data
Bank. Nucleic Acids Res. 2000, 28, 235−242.
(23) PDB code 3CGO: Buckley, G. M.; Ceska, T. A.; Fraser, J. L.;
Gowers, L.; Groom, C. R.; Higueruelo, A. P.; Jenkins, K.; Mack, S. R.;
Morgan, T.; Parry, D. M.; Pitt, W. R.; Rausch, O.; Richard, M. D.;
Sabin, V. IRAK-4 inhibitors. Part II: a structure-based assessment of
imidazo[1,2-a]pyridine binding. Bioorg. Med. Chem. Lett. 2008, 18,
3291−3295.
(24) PDB code 2B55: Yue, E. W.; Higley, C. A.; Dimeo, S. V.; Carini,
D. J.; Nugiel, D. A.; Benware, C.; Benfield, P. A.; Cox, S.; Burton, C.
R.; Grafstrom, R. H.; Sharp, D. M.; Sisk, L. M.; Boylan, J. F.;
Muckelbauer, J. K.; Smallwood, A. M.; Chen, H.; Chang, C.-H.; Seitz,
S. P.; Trainor, G. L. Synthesis and evaluation of indenopyrazoles as
cyclin-dependent kinase inhibitors. 3. Structure activity relationships at
C3(1,2). J. Med. Chem. 2002, 45, 5233−5248.
(25) PDB code 2R4B: Wood, E. R.; Shewchuk, L. M.; Ellis, B.;
Brignola, P.; Brashear, R. L.; Caferro, T. R.; Dickerson, S. H.; Dickson,
H. D.; Donaldson, K. H.; Gaul, M.; Griffin, R. J.; Hassell, A. M.; Keith,
B.; Mullin, R.; Petrov, K. G.; Reno, M. J.; Rusnak, D. W.; Tadepalli, S.
M.; Ulrich, J. C.; Wagner, C. D.; Vanderwall, D. E.; Waterson, A. G.;
Williams, J. D.; White, W. L.; Uehling, D. E. 6-Ethynylthieno[3,2-d]-
and 6-ethynylthieno[2,3-d]pyrimidin-4-anilines as tunable covalent
modifiers of ErbB kinases. Proc. Natl. Acad. Sci. U.S.A. 2008, 105,
2773−78.
(6) Schulze, W. X.; Deng, L.; Mann, M. Phosphotyrosine interactome
of the ErbB-receptor kinase family. Mol. Syst. Biol. 2005, 1, 2005.0008.
(7) Engelman, J. A.; Janne, P. A.; Mermel, C.; et al. ErbB-3 mediates
̈
phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell
lung cancer cell lines. Proc. Natl. Acad. Sci. U.S.A. 2005, 102, 3788−93.
(8) Barker, A. J.; Gibson, K. H.; Grundy, W.; Godfrey, A. A.; Barlow,
J. J.; Healy, M. P.; Woodburn, J. R.; Ashton, S. E.; Curry, B. J.; Scarlett,
L.; Henthorn, L.; Richards, L. Studies leading to the identification of
ZD1839 (Iressa): an orally active, selective epidermal growth factor
receptor tyrosine kinase inhibitor targeted to the treatment of cancer.
Bioorg. Med. Chem. Lett. 2001, 11, 1911−1914.
(9) Hennequin, L. F. A.; Ballard, P.; Boyle, F. T.; Delouvrie, B.;
Ellston, R. P. A.; Halsall, C. T.; Harris, C. S.; Hudson, K.; Kendrew, J.;
Pease, J. E.; Ross, H. S.; Smith, P.; Vincent, J. L. Novel 4-
anilinoquinazolines with C-6 carbon-linked side chains: Synthesis
and structure−activity relationship of a series of potent, orally active,
EGF receptor tyrosine kinase inhibitors. Bioorg. Med. Chem. Lett. 2006,
16, 2672−2676.
(10) Ballard, P.; Bradbury, R. H.; Harris, C. S.; Hennequin, L. F. A.;
Hickinson, M.; Kettle, J. G.; Kendrew, J.; Klinowska, T.; Ogilvie, D. J.;
Pearson, S. E.; Williams, E. J.; Wilson, I. Inhibitors of epidermal
growth factor receptor tyrosine kinase: Optimization of potency and in
vivo pharmacokinetics. Bioorg. Med. Chem. Lett. 2006, 16, 4908−4912.
(11) Ballard, P.; Bradbury, R. H.; Harris, C. S.; Hennequin, L. F. A.;
Hickinson, M.; Johnson, P. D.; Kettle, J. G.; Klinowska, T.; Leach, A.
G.; Morgentin, R.; Pass, M.; Ogilvie, D. J.; Olivier, A.; Warin, N.;
Williams, E. J. Inhibitors of epidermal growth factor receptor tyrosine
kinase: Novel C-5 substituted anilinoquinazolines designed to target
the ribose pocket. Bioorg. Med. Chem. Lett. 2006, 16, 1633−1637.
(12) Ballard, P.; Bradbury, R. H.; Hennequin, L. F. A.; Hickinson, D.
M.; Johnson, P. D.; Kettle, J. G.; Klinowska, T.; Morgentin, R.; Ogilvie,
D. J.; Olivier, A. 5-Substituted 4-anilinoquinazolines as potent,
selective and orally active inhibitors of erbB2 receptor tyrosine kinase.
Bioorg. Med. Chem. Lett. 2005, 15, 4226−4229.
(13) Ballard, P.; Barlaam, B. C.; Bradbury, R. H.; Dishington, A.;
Hennequin, L. F. A.; Hickinson, D. M.; Hollingsworth, I. M.; Kettle, J.
G.; Klinowska, T.; Ogilvie, D. J.; Pearson, S. E.; Scott, J. S.; Suleman,
A.; Whittaker, R.; Williams, E. J.; Wood, R.; Wright, L. Neutral 5-
substituted 4-anilinoquinazolines as potent, orally active inhibitors of
erbB2 receptor tyrosine kinase. Bioorg. Med. Chem. Lett. 2007, 17,
6326−6329.
(14) Barlaam, B.; Ballard, P.; Bradbury, R. H.; Ducray, R.; Germain,
H.; Hickinson, D. M.; Hudson, K.; Kettle, J. G.; Klinowska, T.;
Magnien, F.; Ogilvie, D. J.; Olivier, A.; Pearson, S. E.; Scott, J. S.;
Suleman, A.; Trigwell, C. B.; Vautier, M.; Whittaker, R. D.; Wood, R. A
new series of neutral 5-substituted 4-anilinoquinazolines as potent,
orally active inhibitors of erbB2 receptor tyrosine kinase. Bioorg. Med.
Chem. Lett. 2008, 18, 674−678.
E
dx.doi.org/10.1021/ml400146c | ACS Med. Chem. Lett. XXXX, XXX, XXX−XXX